Belgium-based biopharmaceutical firm UCB has expanded its collaboration with technology company Microsoft to accelerate discovery and development of drugs for people living with severe diseases in immunology and neurology.
GlaxoSmithKline has signed a €150m collaboration agreement with German global pharmaceutical company CureVac in a bid to jointly develop next-generation mRNA vaccines for Covid-19.
A new study claims palbociclib, an approved breast cancer drug, can treat an aggressive form of the cancer, bringing hope to thousands of afflicted women in the UK.
American pharma giant Merck has announced that it has discontinued the development of its SARS-CoV-2/Covid-19 vaccine candidates V590 and V591, after they performed poorly in phase 1 clinical trials.
Pfizer and BioNTech have revealed results of an in vitro study that offers additional data on the capability of sera obtained from people who were immunised with their Covid-19 vaccine, BNT162b2, to neutralise the B.1.1.7 lineage (VOC 202012/01).
Gritstone Oncology, a biotech firm developing vaccines, has announced that it is advancing the development of a second generation vaccine against Covid-19.
KSQ Therapeutics has joined forces with Japan-based Takeda Pharmaceutical to research, develop, and commercialise novel immuno-oncology therapies.
Amneal Pharmaceuticals and Kashiv BioSciences announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC (“Amneal”), a wholly-owned subsidiary of the Company, will acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“Kashiv Specialty”), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.
BeiGene announced a collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan.
French drugmaker Sanofi has agreed to acquire clinical-stage biopharmaceutical company Kymab in a deal valued at around $1.45bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.